Impact of Craig-Hallum Downgrade on Skye Bioscience (SKYE) Stock

• Craig-Hallum downgraded SKYE from a Buy to a Hold rating, impacting its stock price.

• Despite the Nasdaq Composite's gains, SKYE shares fell sharply, indicating mixed market performance.

• The stock's volatility and recent performance may influence investor caution and interest.

Skye Bioscience, trading under the symbol SKYE on the NASDAQ, is a company involved in the development of pharmaceutical products. On October 6, 2025, Craig-Hallum downgraded SKYE from a Buy to a Hold rating, with the stock priced at $1.91. This downgrade reflects a cautious stance on the stock's future performance.

Despite the Nasdaq Composite gaining over 150 points, Skye Bioscience shares experienced a sharp decline, as highlighted by Benzinga. This divergence indicates mixed performance within the U.S. stock market. SKYE's current price is $1.90, showing a significant decrease of 60% from its previous levels.

The stock has fluctuated between a low of $1.77 and a high of $2.30 during the day. Over the past year, SKYE has seen a high of $5.96 and a low of $1.14. This volatility suggests uncertainty in the stock's performance, which may have influenced Craig-Hallum's decision to downgrade the stock.

Skye Bioscience's market capitalization is approximately $58.88 million, with a trading volume of 13.21 million shares. This indicates a moderate level of investor interest, despite the recent downgrade and price decline. Investors may be cautious due to the stock's recent performance and market conditions.